NCT02934061View on ClinicalTrials.gov

Study to Assess the Efficacy and Safety of Tizaspray® Versus Sirdalud®, in Patients With Acute Low Back Pain

PHASE3CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

January 31, 2017

Study Completion Date

February 28, 2017

Conditions
Low Back Pain
Interventions
DEVICE

Tizaspray® administered intranasally

0,5 mg Tizaspray® administered intranasally

DRUG

Sirdalud® 2 mg tablets administered

Sirdalud® 2 mg tablets administered in patients with acute low back pain

Trial Locations (1)

300209

Opera Contract Research Organization SRL, Timișoara

All Listed Sponsors
collaborator

Opera CRO, a TIGERMED Group Company

OTHER

collaborator

Latis S.r.l.

INDUSTRY

lead

MDM S.p.A.

OTHER

NCT02934061 - Study to Assess the Efficacy and Safety of Tizaspray® Versus Sirdalud®, in Patients With Acute Low Back Pain | Biotech Hunter | Biotech Hunter